Deals
Advent Is Said to Near Deal to Acquire Sanofi Generics Unit
- Drugmaker may announce accord with buyout firm in coming days
- European generics unit could be valued at 2 billion euros
This article is for subscribers only.
Advent International Corp. is close to acquiring Sanofi’s European generics division in a deal valued at about 2 billion euros ($2.5 billion) including debt, people with knowledge of the matter said.
The French drugmaker’s board is scheduled to meet as early as Monday to sign off on the deal, which could be announced in coming days, the people said, asking not to be identified because the deliberations are private. No final decision has been made and the talks may still fall apart, they said.